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sister (20 x 106 CD34 cells/kg). As acute
graft versus host disease prophylaxis she
received cyclosporin A (1,5 mg/kg from
day - 1). From day +16 we observed
aGVHD ,,0 in the skin and gastrointestinal
tract. Administration of metylprednisolon
in max. dose of 1,5 mg/kg proved effect-
tive. No toxicity attributable to the con-
ditioning regimen was noted. She was
discharged on day +36.
Complete donor chimerism was reached
by day + 14 and has not changed since
then. On day + 183 the girl is doing well
with stable haematopoiesis of donor origin.
We conclude that preparative regimen
containing treosulfan is a reasonable
option in heavily treated children under-
going bone marrow transplantation.
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Mitochondrial protein bcl-2 is an impor-
tant inhibitor of apoptosis. Blocking
expression of bcl-2 gene by antisense
oligonucleotides (AS-ODN) administration
may result with higher chemosensitivity
of leukemic cells. C-myb is one of the re-
gulatory proteins of cell cycle. Decreasing
its level by antisense oligonucleotides
(AS-ODN) may result with decreased
leukemic cells proliferation.
infusion via central vein catheter at dose
of 0,5-1,2 mg/kg/day. Duration of the tre-
atment was 10 days. We used three
protocols of chemotherapy combined with
antisense infusion. The first protocol was
based on Fludarabine and Cytarabine
(4 patients), the second on Topotecan and
Cyclophosphamide (2 patients). If treat-
ment based on those protocols was not
effective, infusion of AS-ODN with chemo-
therapy based on Paclitaxel and Doxo-
rubicin was introduced (2 patients). G-CSF
was administrated in each case.
No side effects were observed during
AS-ODN administration. The expression
of bcl-2 protein was measured in four
patients (FACS analysis). The decreasing
expression of bcl-2 protein more than
1/3 of the initial value was detected in two
cases. One complete remission has been
achieved lasting 3 months. Two patients
died due to disease's progress.
The preliminary observation showed that
antisense administration is safe and has
no clinically relevant side effects. Higher
dose and repeated AS-ODN infusion
seems to be necessary to achieve better
disease control.
boys/girls age sex dgn relapse Post auto-
PBSeT
Patient A 17 years m ALL-T II 1
Patient B 9 years m ALL-oreB II 1
Patient C 11 years m NHL-LCAL IV 2
Two boys with relapsed ALL after auto
PBSCT and 1 boy with relapsed NHL after
second auto PBSCT were treated with
AS-ODN.
Antisense oligonucleotide anti bcl-2
(18-mer) or anti C-myb was modified
by thioester group supplementation. It was
administrated as a continuous 24-hour
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